Taking the company as a whole, the generic Lovenox program would be a feather in the cap and be the near term cash cow product for them. But the real guts to establishing the company as a unique entity is the ability to produce their own drugs from the ground up with their technology. M118 and there foray into oncology could propel them into the big time in the eyes of big pharma. Though when concerned with their stock price, M118 and oncology are so far down the road to contributing to their bottom line than I'm afraid without generic Lovenox approval MNTA could languish in the 4 to 5 dollar range for the next 12 months.
I still like the chances for M-Enoxaparin approval this year. I like the top notch management MNTA has as well as the technology and know-how.
Market Data 
Markets 
AI
